linjc16/ctgov huggingface dataset:
Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to identify the healing of aneurysms in three month use Optical Coherence Tomography image to measure outcomes in post coiled aneurysms. Endovascular therapeutic coiling is a widely used procedure in the management of aneurysms, which is an angiogram .

Detailed Description
-----------------
Subarachnoid hemorrhage secondary to ruptured cerebral aneurysms, unruptured aneurysms that are being treated using endovascular coiling. The researcher can use Optical Coherence Tomography image at the rime of initial angiography with unruptured aneurysms, and at the three month follow up catheter angiogram. Optical Coherence Tomography image can follow the therapeutic coiling of the aneurysm, the 6F endocatheter and the microcatheter used for the coiling procedure place in the internal carotid artery and parent artery lumen follow with Optical Coherence Tomography fiber insert through the lumen of the tube on which the image can obtain.

Official Title
-----------------
Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.

Conditions
-----------------
Cerebral Aneurysm

Intervention / Treatment
-----------------
* Device: Optical Coherence Tomography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years of age Subject diagnosis of aneurysm and undergoing endovascular coiling Exclusion Criteria: Pregnant women Age ≤ 18 years of age Patient presenting emergently with acutely ruptured aneurysms

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Diagnostic Tool<br>Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing. | Device: Optical Coherence Tomography<br>* Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.<br>* Other names: Optical Coherence Tomography Imaging;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Aneurysm Healing | Optical Coherence Tomography Imaging | up to 12 months |
Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and efficacy of product 0405 in pediatric subjects with Mild to Moderate Atopic Dermatitis.

Detailed Description
-----------------
Treatment medication will be administered topically twice daily for 28 days

Official Title
-----------------
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Product 0405 To A Vehicle Control In The Treatment Of Mild To Moderate Atopic Dermatitis In Pediatric Subjects

Conditions
-----------------
Atopic Dermatitis

Intervention / Treatment
-----------------
* Drug: Product 0405
* Drug: Placebo for Product 0405


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical Diagnosis of Atopic Dermatitis Good health with the exception of Atopic Dermatitis Percent body surface area minimum requirements Exclusion Criteria: Subjects who are pregnant, nursing or planning a pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 3 Months
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Product 0405<br>Topical active investigational Product 0405 | Drug: Product 0405<br>* Product 0405 will be administered topically twice daily for 28 days.<br>|
| Placebo Comparator: Placebo for Product 0405<br>Topical Placebo for Product 0405 | Drug: Placebo for Product 0405<br>* Placebo for Product 0405 will be administered topically twice daily for 28 days.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Statistically significant superiority of the test Product 0405 to the vehicle | Statistically significant superiority of the test Product 0405 to the vehicle | 28 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of success based on the Investigators Static Global Assessment and the Clinical Signs and Symptoms (erythema, scaling) at the end of treatment. | Incidence of success based on the Investigators Static Global Assessment and the Clinical Signs and Symptoms (erythema, scaling) at the end of treatment. | 28 days |
Bifeprunox Extension to Extension Study in Patients With Schizophrenia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to provide access to bifeprunox for patients, who have completed previous studies with bifeprunox, and require continued treatment with bifeprunox, other treatment not being adequate. A further purpose is to investigate the safety and side-effects of bifeprunox during long-term treatment.

Detailed Description
-----------------
This is a non-controlled, open-label, flexible-dose, international multi-centre extension study. The patient population consists of male and female patients with schizophrenia, who have completed open-label bifeprunox studies 10206 or 10265, and require continued treatment with bifeprunox, other treatments not being feasible as judged by the investigator.

Official Title
-----------------
An Open-label Safety Study of Bifeprunox Investigating Flexible Doses of 20, 30, or 40mg/Day in Patients With Schizophrenia Who Have Completed Studies 10206 or 10265

Conditions
-----------------
Schizophrenia

Intervention / Treatment
-----------------
* Drug: Bifeprunox


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients, suffering from schizophrenia, having completed studies 10206 or 10265 Otherwise healthy Female patients of non-childbearing potential, or non-pregnant, not breast-feeding women using adequate contraception The patient must be in need of treatment with bifeprunox (that is, the switch to another compound is not feasible) Exclusion Criteria: Current Axis I primary psychiatric diagnosis other than schizophrenia Significant risk of suicide and/or violent behaviour Other psychiatric, neurological or behavioural disorders that may interfere with study conduct Substance or alcohol abuse, current cannabis dependence Clinically significant physical illness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Bifeprunox<br> | Drug: Bifeprunox<br>* Flexible dosage: 20, 30, or 40 mg/day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events, clinical safety laboratory tests, vital signs, ECGs, physical and neurological examinations, abnormal movement scales (AIMS, BARS, SAS) |  | Assessments every 4 to 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CGI-S |  | Assessments every 4 to 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Open-label, Flexible-dose, Extension, Safety study
A Novel Method for Enhancement of Standard Rest Electrocardiograms (ECG) Provides New Parameters for Early Detection of Coronary Artery Disease (CAD)

Study Overview
=================
Brief Summary
-----------------
The investigators aim to determine whether a new method of enhancing and improving ECG acquisition, analysis and display is effective. The investigators will perform superimposition and summation of multiple standard ECG cycles, in the same lead, by temporal alignment to the peak R wave and voltage alignment to an improved baseline at the T-P segment.

Conditions
-----------------
Cardiovascular Diseases

Intervention / Treatment
-----------------
* Procedure: Routine coronary angiogram


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing routine coronary angiogram Exclusion Criteria: Patients with significant irregular heart rhythm Patients with heart failure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Routine coronary angiogram patients<br> | Procedure: Routine coronary angiogram<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ECG Voltage spread | We will measure the voltage spread at the S-T and P-R intervals after superimposition and summation of multiple standard ECG cycles in the same lead, by temporal alignment to the peak R wave and voltage alignment to an improved baseline at the T-P segment. | One month |
The Effect of Saline Irrigation in the Peritoneal Cavity at Cesarean Delivery

Study Overview
=================
Brief Summary
-----------------
The investigators hypotheised that irrigating the abdominal cavity with saline at the time of cesarean delivery will increase Gastrointestinal System Disfunction without maternal infectious morbidity(especially febril morbidity).

Official Title
-----------------
The Effect of Saline Irrigation in the Peritoneal Cavity at Cesarean Delivery on Maternal Morbidity and Gastrointestinal System Outcome

Conditions
-----------------
Postoperative Enfectious Morbidity, Postoperative GİS Functionally Recovery

Intervention / Treatment
-----------------
* Procedure: irrigation in the peritoneal cavity


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Elective cesarean delivery Gestational age greater 38 weeks Exclusion Criteria: chorioamnıonıtıs type 1 diabetes mellitus placenta previa and acreata prior severe gastrointestional disease emergency cesarean delivery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 44 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| saline irrigation<br>irrigation group:saline irrigation after uterine wall closed control group:no irrigation after uterine wall closed | Procedure: irrigation in the peritoneal cavity<br>* irrigation in the peritoneal cavity after uterine wall closed at cesarean<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative gastrointestinal system disturbance | ıntraoperative and postoperative nausea,emesiz and requirement antıemetic drug | postoperativeone weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative febril morbidity | postoperative endometritis,febril morbidity | postoperative six weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
focus of study is postoperative enfectious morbidity and postoperative GİS functionally recovery
Efficacy of Oxepa Enteral Feeding in LTAC (Long Term Acute Care Hospital) Patients on Chronic Ventilation- a Pilot Study

Study Overview
=================
Brief Summary
-----------------
Patients with mechanical ventilation have shown improved weaning rates when enteral tube feeding high in EPA, GLA and antioxidants were fed to patients in the critical care setting. LTAC Patients on chronic mechanical ventilation will have decreased days an mechanical ventilation, decreased mortality rates and decreased organ failure when fed an enteral product high in EPA, GLA and antioxidants compared to an isotonic high fiber enteral nutrition product.

Official Title
-----------------
Efficacy of the Use of Enteral Feeding High in EPA,GLA and Antioxidants in LTAC Patients on Chronic Ventilation- a Pilot Study

Conditions
-----------------
Acute Lung Injury, Mechanical Ventilation Complication, Dietary Modification

Intervention / Treatment
-----------------
* Other: Oxepa
* Other: Jevity 1.5


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: >18 years old with Respiratory failure on mechanical ventilation with failure to wean Diagnosis of ARDS (Acute respiratory Distress Syndrome) Bilateral infiltrates - Exclusion Criteria: History Of pulmonary fibrosis, Terminal illness/ malignancies, <28 day life expectancy, Hemodialysis, Active bleeding or bleeding disorder: DIC ( Disseminated intravascular Coagulation), Sickle Cell Anemia, Hemophilia Hemorrhagic or ischemic stroke, Liver failure, Head trauma with Glasgow coma scale score of <5, Immunosuppression: WBC(White Blood Cell Count) <5000, HIV positive, use of immunosuppressant drugs, Pregnancy, and Heart Failure with EF(Ejection Fraction) <35% -

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Oxepa<br>Other: Therapeutic nutrition with EPA, GLA and antioxidants. | Other: Oxepa<br>* Therapeutic nutrition with EPA, GLA< and antioxidants<br>|
| Active Comparator: Jevity 1.5<br>Other: Jevity 1.5 Complete Balanced Nutrition with Fiber . | Other: Jevity 1.5<br>* Complete balanced nutrition with a unique fiber blend<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of days on mechanical ventilation |  | 14 days from start of enteral feeding |
Fertility Surgery, Prospective Analysis

Study Overview
=================
Brief Summary
-----------------
From September 2006 a prospective cohort study is conducted among all patients operated at the Leuven University Fertility Centre to evaluate clinical and economical outcome after CO2 laser laparoscopic fertility surgery.

Detailed Description
-----------------
The main outcome measurements are postoperative complications, pain, quality of life, sexual satisfaction, economic life circumstances, cumulative pregnancy rate and cumulative recurrence rate of endometriosis.

Official Title
-----------------
Quality Control in Surgical Diagnosis and Treatment of Endometriosis.

Conditions
-----------------
Endometriosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients operated at the Leuven University Fertility Centre of the Department of Obstetrics and Gynaecology of the University Hospitals Leuven, Leuven,Belgium, from September 2006 to August 2008. Exclusion Criteria: patients of other than the Dutch language

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients operated at the LUFc<br>All patients operated at the Leuven University Fertility Centre (LUFc) between september 2006 and August 2008. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| complication rate, quality of life, pain, sexual activity, economic life circumstances, pregnancy rate, reintervention rate, recurrence rate |  | 1 month preop, 6 - 12 - 18 and 24 months postop | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Endometriosis, Fertility Surgery, Quality of Life, Pain, Sexual Function, Health economics, Recurrence, Pregnancy
A Retrospective EGFR Mutation Status Study in Chinese NSCLC Patients Using Paired Plasma and Tissue Samples

Study Overview
=================
Brief Summary
-----------------
EGFR mutations plays an essential role in EGFR-TKIs treatment. However, for some patients, tissue samples are not available. The purpose of this study is to determine whether blood sample is feasible for EGFR mutation detection.For late stage NSCLC, we hypothesis plasma sample is an alternative for detecting EGFR mutations.

Conditions
-----------------
Carcinoma, Non-Small-Cell Lung

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Non-small cell lung cancer Available plasma and pathologically confirmed tissue slices(pre-chemo and pre-radio therapy) Informed Consent Exclusion Criteria: N/A

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Early Stage<br> | |
| Late Stage<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine the consistence of EGFR mutation status in paired tissue and plasma samples |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine the EGFR mutation status in Chinese NSCLC |  | 3month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Carcinoma, Non-Small-Cell Lung, erbB-1
Effectiveness of the New Perilaryngeal Airway in Comparison With the Laryngeal Mask Airway

Study Overview
=================
Brief Summary
-----------------
The Laryngeal Mask Airway (LMA) has been used widely for different patients and found to be highly safe for adult and pediatric patients. However, the LMA has some limitations and weaknesses (e.g. more insertion attempts in 5% to 10 % of all cases. Despite the easy insertion of the LMA, it is crucial to check correct placement of the LMA airway.

Official Title
-----------------
Effectiveness of the New Perilaryngeal Airway (CobraPLA™) in Comparison With the Laryngeal Mask Airway (LMA™) to Improve Oropharyngeal Leak Pressure Among Obese and Overweight Patients

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Device: COBRA
* Device: LMA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI between 25 to 35 kg/m2 scheduled for surgery being older than 18 years Mallampati class I-III and BMI between 25 and 35 Exclusion Criteria: pregnancy morbid obese (BMI>35 kg/m2) a known difficult airway gastro-oesophageal reflux pharyngeal pathology emergency operation with full stomach

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CobraPLA<br>Patients will randomly assign to either LMA or Cobra PLATM | Device: COBRA<br> <br> |
| Experimental: LMA<br>Patients will randomly assign to either LMA or Cobra PLATM | Device: LMA<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oropharyngeal leak |  | Up to 1 hours | 
| Time to intubation | Time to intubation was measured from inserting of the device to the patient's month while connecting the breathing circuit | Up to 1 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| successful intubation attempt | A successful intubation attempt was recognized if: the breathing circuit connected, the EtCO2 trace was revealed, and no air leak was detected at airway pressures of 15 cm H2O | Up to 1 hours | 
| incidence of sore throat |  | Up to 1 hours | 
| incidence of dysphasia |  | Up to 1 hours | 
| incidence of postoperative blood staining on mask |  | Up to 1 hours |
Pulsed Dye Laser and Intense Pulsed Light (IPL) for the Treatment of Telangiectasia and Skin Redness

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to compare efficacy and adverse effects of pulsed dye laser and intense pulsed light in patients with skin telangiectasia and redness.

Official Title
-----------------
Pulsed Dye Laser and Intense Pulsed Light for the Treatment of Telangiectasia and Skin Redness

Conditions
-----------------
Telangiectasis, Erythema

Intervention / Treatment
-----------------
* Device: Pulsed dye laser
* Device: Intense pulsed light


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years or older Skin types I, II, III No previous laser or IPL treatment for the condition Exclusion Criteria: Younger than 18 years old Skin types IV, V, or VI Pregnant or lactating women Previous laser or IPL treatment for the condition Recent exposure to sun or sun-beds Treatment with oral retinoid within 6 months Tendency to produce hypertrophic scars or keloids

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Pulsed dye laser|nan|
|Device: Intense pulsed light|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Telangiectasia, Skin redness